Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study

PURPOSE: This study evaluated the potential effect of trastuzumab on the electrocardiogram (ECG) QT interval and assessed the potential pharmacokinetic interaction between trastuzumab and carboplatin. Here, we report the QT and safety results. METHODS: Patients with metastatic or inoperable HER2-pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Na, Redfern, Charles H., Gordon, Michael, Eppler, Stephen, Lum, Bert L., Trudeau, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236615/
https://www.ncbi.nlm.nih.gov/pubmed/25344761
http://dx.doi.org/10.1007/s00280-014-2603-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236615/
https://www.ncbi.nlm.nih.gov/pubmed/25344761
http://dx.doi.org/10.1007/s00280-014-2603-9

Ejemplares similares